ArticleContemporary oncology (Poznan, Poland)2025
Real-world predictive models for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer.
Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of pre-treatment systemic inflammation indices (systemic immune-inflammation index, systemic inflammation response index, and inflammatory benchmark index) in predicting mortality risk in patients with pancreatic cancer.Contemporary oncology (Poznan, Poland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In 2020 in Poland a total of 3 589 people had pancreatic cancer (PC). Only 20% of patients were diagnosed with surgical disease. New therapeutic options that demonstrate statistically significant improvements in overall survival (OS) and progression-free survival (PFS) are still being sought. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in routine practice. Material and methods: The aim of the clinical study was a retrospective analysis of the medical history of 182 patients with the diagnosis of metastatic pancreatic cancer (mPC), who were treated with combination treatment of nab-paclitaxel with gemcitabine (GEM-NAB) between February 2017 and September 2023. Our study also aimed to identify important population-based predictors for survival in patients diagnosed with mPC. Results: The median age was 66 years (range 37-84 years). Median OS was 9.2 months (95% CI: 8.3-10.03), and median PFS was 5.47 months (95% CI: 4.83-6.1); 26 patients achieved either a partial or complete response (overall response rate 14%). GEM-NAB was well tolerated. The most common adverse events were alopecia, fatigue, neutropenia, anemia, and peripheral neuropathy. This study identified specific clinical and laboratory parameters (neutrophil to lymphocyte ratio, antigen Ca 19.9, mechanical jaundice, peripheral neuropathy and 2 Conclusions: Our results confirm the efficacy and tolerability of GEM-NAB as standard first-line treatment in patients with mPC. Among the factors having the greatest impact on OS was the 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.